A phase II enrolling 40 HER2-positive ABC with progressive disease after previous CNS-directed therapy including whole brain radiotherapy, surgery, or radiosurgery, evaluated single-agent neratinib 240 mg OD and found limited activity (CNS ORR of 8%) [51]. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.